Clinical correlates of 'brcaness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy

Annals of Oncology

Volumn 23, Issue 9, 2012, Pages 2301-2305

  Oonk, A M M ^a   Van Rijn, C ^a   Smits, M M ^a   Mulder, L ^b   Laddach, N ^c   Savola, S P ^c   Wesseling, J ^b   Rodenhuis, S ^b   Imholz, A L T ^a   Lips, E H ^b  

^a DEVENTER HOSPITAL   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c MRC HOLLAND   (Netherlands)

Author keywords

Adjuvant chemotherapy; Conventional chemotherapy; Genomic hybridization; Homologous recombination; Survival; Triple negative breast cancer

Indexed keywords

BRCA1 PROTEIN; CYCLOPHOSPHAMIDE; DNA; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; DRUG EFFECT; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOCAL METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; METHOTREXATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAXOIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865552486     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr621     Document Type: Article

References (19)

1. Lips EH, Mulder L, Hannemann J et al. Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. Ann Oncol 2011; 22(4): 870-876.
2. Vollebergh MA, Lips EH, Nederlof PM et al. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol 2011; 22(7): 1561-1570.
3. Scully R, Ganesan S, Vlasakova K et al. Genetic analysis of BRCA1 function in a defined tumor cell line. Moll Cell 1999; 4(6): 1093-1099.
4. Tassone P, Tagliaferri P, Perricelli A et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003; 88(8): 1285-1291.
5. Rottenberg S, Nygren AO, Pajic M et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. PNAS 2007; 104(29): 12117-12122.
6. Ronde de JJ, Hanneman J, Halfwerk H et al. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 2010; 119(1): 119-126.
7. Schouten JP, McElgunn CJ, Waaijer R et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002; 30: e57.
8. Lips EH, Laddach N, Savola SP et al. Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness. Breast Cancer Res 2011; 13(5): R107.
9. Joosse SA, Beer van EH, Tielen IHG et al. Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Res Treat 2009; 116: 479-489.
10. Hogervorst FB, Nederlof PM, Gille JJ et al. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer res 2003; 63(7): 1449-1453.
11. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002; 99: 6567-6572.
12. Konstantinopoulos PA, Spentzos D, Karlan BY et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010; 28(22): 3555-3561.
13. Silver DP, Richardson AL, Eklund AC et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28: 1145-1153.
14. Goffin JR, Chappuls PO, Bégin LR et al. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma. Cancer 2003; 97(3): 527-536.
15. Kriege M, Seynaeve C, Meijers-Heijboer H et al. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009; 27(23): 3764-3771.
16. Foulkes WD, Metcalfe K, Hanna W et al. Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer 2003; 98(8): 1569-1577.
17. Asakawa H, Koizumi H, Koike A et al. Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins. Breast cancer Res 2010; 12(2): R17.
18. Swisher EM, Sakai W, Karlan BY et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 2008; 68: 2581-2586.
19. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361(2): 123-134.